Interested in Launching an Investigator Initiated Study (IIS) ?
Debiopharm is committed to supporting rigorous and scientifically sound research that furthers our understanding of diseases and unlocks the potential for new treatments. We focus our research and development in oncology and infectious diseases, as we believe we can make a significant contribution to improving patient lives.

An Investigator Initiated Study (IIS), also known as Investigator Sponsored Trial (IST) or Investigator Initiated Trial (IIT) are clinical trials where a qualified, non-commercial entity like an academic institution, individual researcher, or independent group designs, conducts, and manages the entire study. These studies are independent of pharmaceutical companies but could involve their resources and expertise.
Our Strategic Areas of Interest
We're seeking proposals from qualified investigators with promising concepts aligned with our strategic areas of interest.
-
Monotherapy approaches in unexplored indications, backed by strong scientific rationale
-
Combinations of Debiopharm assets with targeted therapies, ADCs, immune checkpoint inhibitors, RLTs in solid tumors
-
Strong scientific rationale
-
Concepts exploring combinations aiming to improve efficacy or to overcoming resistance to DNA damage repair (DDR)-based drugs
Examples of an ongoing IIS
-
MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer
Read Press Release

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer
Read Press Release